Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    9393757 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Trastuzumab, Docetaxel;   Drug: Trastuzumab, Docetaxel, Bevacizumab;   Drug: Trastuzumab+Docetaxel+NPLD;   Drug: Trastuzumab+Docetaxel+NPLD+Bevacizumab

Indicates status has not been verified in more than two years